Tarsus Pharmaceuticals Inc (TARS) gains 3.53% for July 21

Equities Staff  |

Tarsus Pharmaceuticals Inc (NASDAQ: TARS) shares gained 3.53%, or $0.9 per share, to close Wednesday at $26.39. After opening the day at $25.49, shares of Tarsus fluctuated between $26.53 and $24.78. 38,248 shares traded hands a decrease from their 30 day average of 76,369. Wednesday's activity brought Tarsus’s market cap to $541,640,869.

About Tarsus Pharmaceuticals Inc

Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline to address a number of diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 for the treatment of Demodex blepharitis. TP-03 is also being developed for the treatment of Meibomian Gland Disease.

Visit Tarsus Pharmaceuticals Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Tarsus Pharmaceuticals Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Tarsus Pharmaceuticals Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content